Kallanthottathil G. Rajeev, Ph.D.
Vice President, CMC
Kallanthottathil Rajeev (Rajeev) has over 25 years of expertise in nucleic acid chemistry and 18 years of experience in developing nucleic acid therapeutics. Prior to joining Verve, Rajeev served as senior fellow of intellectual property and as a senior director of drug discovery at Alnylam Pharmaceuticals. In his 14 years with the drug discovery team at Alnylam, Rajeev played a key leadership role in the development of siRNA GalNAc conjugate and LNP delivery platforms, and in the design and evaluation of siRNAs for clinical development. During his tenure at Alnylam, Rajeev contributed to the developments of several RNAi therapeutics that are in early- to late-stage clinical development, as well as contributing to the first-ever RNAi drug to secure regulatory approval in the U.S. and the EU, Onpattro®(patisiran), approved in 2018. Prior to Alnylam, Rajeev worked for Ionis (formerly Isis) Pharmaceuticals on high-affinity antisense oligonucleotides (ASO) and ASO-small molecule conjugates. He has co-authored more than 50 peer-reviewed manuscripts and is a co-inventor of more than 100 issued U.S. patents and over 70 PCT International Publications. Rajeev earned his Ph.D. in chemistry in the lab of Professor K. N. Ganesh at the National Chemical Laboratory, Pune, India, and was a postdoctoral researcher at the University of Utah, Salt Lake City, where he worked with Professor Arthur D. Broom.